Orient Pharma Co. Ltd.
Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based… Read more
Orient Pharma Co. Ltd. (4166) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: 0.039x
Based on the latest financial reports, Orient Pharma Co. Ltd. (4166) has a cash flow conversion efficiency ratio of 0.039x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$68.94 Million) by net assets (NT$1.77 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Orient Pharma Co. Ltd. - Cash Flow Conversion Efficiency Trend (2019–2023)
This chart illustrates how Orient Pharma Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Orient Pharma Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orient Pharma Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Klingelnberg AG
SW:KLIN
|
-0.084x |
|
Etteplan Oyj
HE:ETTE
|
0.138x |
|
1ST SUMMIT BANCORP of Johnstown Inc
PINK:FSMK
|
0.000x |
|
SBI Investment KOREA Co. Ltd
KQ:019550
|
-0.020x |
|
Groupe Sfpi
PA:SFPI
|
0.026x |
|
Oregon Pacific Bancorp
PINK:ORPB
|
0.013x |
|
BitFuFu Inc. Class A Ordinary Shares
NASDAQ:FUFU
|
0.000x |
|
Scicom MSC Bhd
KLSE:0099
|
0.038x |
Annual Cash Flow Conversion Efficiency for Orient Pharma Co. Ltd. (2019–2023)
The table below shows the annual cash flow conversion efficiency of Orient Pharma Co. Ltd. from 2019 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | NT$1.67 Billion | NT$-102.99 Million | -0.062x | -690.29% |
| 2022-12-31 | NT$1.09 Billion | NT$11.38 Million | 0.010x | +121.76% |
| 2021-12-31 | NT$1.12 Billion | NT$-53.56 Million | -0.048x | +60.50% |
| 2020-12-31 | NT$1.22 Billion | NT$-147.95 Million | -0.122x | -46.13% |
| 2019-12-31 | NT$1.56 Billion | NT$-129.91 Million | -0.083x | -- |